Shang Hai Zheng Quan Bao·2025-10-28 21:46Group 1 - Shanghai Pharmaceuticals has received approval for the production of Bromperidol Sustained-Release Tablets from the National Medical Products Administration [1][2] - The drug is classified as a Class 3 chemical drug with a specification of 0.18g per tablet and has been registered under the approval number H20255730 [2] - The drug is indicated for the treatment of myasthenia gravis and was originally developed by BAUSCH, first launched in the United States in 1959 [3] Group 2 - As of the announcement date, no other companies in China have listed Bromperidol Sustained-Release Tablets [4] - According to IQVIA data, the procurement amount for Bromperidol Tablets in hospitals in mainland China is approximately RMB 60.29 million for 2024 [5] - The company has invested approximately RMB 16.009 million in research and development for this drug [3] Group 3 - The approval of the drug is expected to enhance the market share and competitiveness of Shanghai Pharmaceuticals, benefiting from national policies that support newly registered generic drugs in medical insurance and procurement [6] - The company aims to leverage this experience for future generic drug applications [6]